COMMUNIQUÉS West-GlobeNewswire

Parexel to Showcase Seven Research Posters and Debut New Hematology Playbook at the European Hematology Association Congress 2026
10/06/2026
Five in-person poster presentations and two virtual posters highlight Parexel’s thought leadership in real - world evidence, comparative outcomes and regulatory insights across hematologic diseases “At the Turning Point [...]
genXtraits, Mendel Biotechnology and AgGene Announce Collaboration to Develop Stress-Resilient Canola Traits
10/06/2026
SAN FRANCISCO, June 10, 2026 (GLOBE NEWSWIRE) -- San Francisco Bay Area based biotechnology firms, genXtraits Inc. (genXtraits) and Mendel Biotechnology, Inc. (Mendel), have announced a joint collaboration with AgGene [...]
RadioMedix Announces Receiving FDA Approval of its Generic Ga-68 PSMA-11 Radiodiagnostic for Prostate Cancer
10/06/2026
Approval follows FDA inspection of RadioMedix’s manufacturing site with no Form 483 observations, underscoring the Company’s radiopharmaceutical manufacturing and quality capabilities HOUSTON, June 10, 2026 (GLOBE [...]
Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting
10/06/2026
BERKELEY, CA, June 10, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a leading digital health company pioneering next-generation biosensing technologies, today issued the following [...]
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
10/06/2026
Additional Orange Book Listed Patent Secured and Composition of Matter Patent is Eligible for 5-Year Extension CAMBRIDGE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a [...]
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
10/06/2026
Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right, which represents the contractual right to receive two contingent cash payments of up to an aggregate of $ [...]
Tris Pharma Announces FDA Grant of Orphan Drug Designation for TRN-257 (Oxybate for Extended-Release Oral Suspension) a Once-Nightly, Low-Sodium Oxybate Product for Idiopathic Hypersomnia
10/06/2026
FDA grants Orphan Drug Designation (ODD) to Tris Pharma’s TRN-257 for the treatment of idiopathic hypersomnia, based on the plausible hypothesis that TRN-257 may be clinically superior to currently available oxybate [...]
DeepHealth Launches Reporting Pro, Bringing AI Automation to Radiology Reporting
10/06/2026
New solution integrates speech recognition, clinical AI findings, measurements, AI-generated impressions and quality assurance SOMERVILLE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI [...]
Tilray Medical Germany Launches ARX™, a New Premium Medical Cannabis Brand Cultivated in Germany
10/06/2026
New Brand Combines Proven Genetics, German Cultivation Expertise, and Rigorous Quality Standards to Support Patients and Healthcare Professionals Across Germany NEUMÜNSTER, Germany, June 10, 2026 (GLOBE NEWSWIRE) -- [...]
Italfarmaco Announces Health Canada Acceptance and Priority Review of New Drug Submission for Givinostat as a Duchenne Muscular Dystrophy Treatment
10/06/2026
Health Canada Priority Review targets an expedited 180-day review period for givinostat, reflecting Italfarmaco’s commitment to Canadian DMD community NDS is based on Italfarmaco’s Phase 3 EPIDYS trial data [...]
Reacta Healthcare Receives Extended MHRA Pharmaceutical Manufacturer’s Licence and GMP Certificate
10/06/2026
DEESIDE, United Kingdom, June 10, 2026 (GLOBE NEWSWIRE) -- Reacta Healthcare, a leading developer and manufacturer of pharmaceutical-grade oral food challenge (OFC) products for food allergy diagnostics, today announces [...]
Italfarmaco annonce l’acceptation du dépôt et l’examen prioritaire par Santé Canada pour la présentation de drogue nouvelle du givinostat dans le traitement de la dystrophie musculaire de Duchenne
10/06/2026
L’examen prioritaire de Santé Canada vise un délai accéléré de 180 jours pour l’examen du givinostat, reflétant l’engagement d’Italfarmaco envers la communauté canadienne touchée par la dystrophie musculaire de Duchenne [...]
IBA Announces Research Collaboration to Strengthen Evidence on the Value of Proton Therapy
10/06/2026
Louvain-la-Neuve, Belgium, June 10, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of proton therapy solutions for the treatment of cancer [...]
CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome
10/06/2026
Builds on positive Phase I safety data and represents a key value-inflection milestone for the Company Advances a potentially disease-modifying approach for fragile X syndrome, a condition with no approved targeted [...]
Cytospire Therapeutics Appoints Samit Hirawat, M.D., as Non-Executive Director
10/06/2026
Dr Hirawat i s the former CMO and Head of Global Drug Development at Bristol Myers Squibb and former EVP and Head of Oncology Development at Novartis Augments Cytospire’s clinical development experience as Cytospire [...]
Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery
10/06/2026
Tokyo, Japan and Cambridge, UK, 10 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)　announces that it has joined OpenFold, a non-profit AI research consortium that promotes the development of open-source AI [...]
Vara receives CE mark for tomosynthesis AI - extending Europe’s leading screening-grade AI portfolio to 3D
10/06/2026
BERLIN, June 10, 2026 (GLOBE NEWSWIRE) -- Vara, the AI company powering more than half of Germany’s organized breast cancer screening program, today received CE class 2b marking under EU MDR for its tomosynthesis (3D [...]
Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
10/06/2026
Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy Paris, June 10, 2026 . Sanofi today announced that the riliprubart MOBILIZE phase 3 study (clinical [...]
China's Leading Brand CUKTECH has Cumulatively Sold Over 150 Million Power Banks Globally, Taking a Further Step Towards Globalization
10/06/2026
CANBERRA, Australia, June 10, 2026 (GLOBE NEWSWIRE) -- Latest data from CUKTECH, a leading Chinese brand, shows that it has cumulatively shipped over 150 million power banks and 20 million chargers. As technology [...]

Pages